Cover Image

Reinduction of hedgehog inhibitors after checkpoint inhibition in advanced basal cell carcinoma: a series of 12 patients

For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.

Saved in:
Bibliographic Details
Main Authors: DeTemple, Viola (Author) , Hassel, Jessica C. (Author) , Sachse, Michael M. (Author) , Grimmelmann, Imke (Author) , Leiter, Ulrike (Author) , Gebhardt, Christoffer (Author) , Eckardt, Julia (Author) , Pföhler, Claudia (Author) , Angela, Yenny (Author) , Hübbe, Hanna (Author) , Gutzmer, Ralf (Author)
Format: Article (Journal)
Language:English
Published: 7 November 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 21, Pages: 1-9
ISSN:2072-6694
DOI:10.3390/cancers14215469
Online Access:Resolving-System, Volltext: https://doi.org/10.3390/cancers14215469
Verlag, Volltext: https://www.mdpi.com/2072-6694/14/21/5469
Get full text
Author Notes:Viola K. DeTemple, Jessica C. Hassel, Michael M. Sachse, Imke Grimmelmann, Ulrike Leiter, Christoffer Gebhardt, Julia Eckardt, Claudia Pföhler, Yenny Angela, Hanna Hübbe and Ralf Gutzmer
Description
Summary:For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.
Item Description:Gesehen am 26.01.2023
Physical Description:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14215469

Similar Items